ABIVAX

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax reports 2023 financial results and operational update

Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)

Abivax appoints Ana Sharma as Vice President, Global Head of Quality

Abivax announces update to obefazimod Phase 2b clinical development program in moderately to severely active Crohn’s disease

Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024

Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months

Abivax 2024 Financial Communication Calendar

Abivax announces the resumption of its liquidity contract

Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference

Abivax announces Closing of its Initial Public Offering on the Nasdaq Global Market

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax announces the pricing of its Initial Public Offering on the Nasdaq Global Market 

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Abivax announces the filing of an amended registration statement, including an estimated initial public offering price range

Abivax announces the start of the roadshow for its proposed global offering and proposed Nasdaq listing

Abivax highlights obefazimod ulcerative colitis program with new data to be presented at the UEG Week 2023

Abivax files registration statement for proposed initial public offering in the United States

Abivax announces the release of its 2023 half-year financial report

Abivax presents first-half 2023 financial results

Abivax provides business and operational update

Abivax appoints Patrick Malloy as Senior Vice President Investor Relations

Abivax secures up to EUR 150M from two structured debt financing transactions

Abivax announces plans to conduct registered public offering in the United States

Abivax announces the appointment of June Lee, M.D. and Troy Ignelzi as Members of the Board of Directors

Abivax receives “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023

Abivax stock included in MSCI Indexes

Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting

Abivax appoints Ida Hatoum as Chief People Officer

Abivax announces its ordinary and extraordinary general meeting of June 5, 2023, and the availability of the preparatory documents